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Management of Levodopa Medication for Older People with Parkinson’s Disease 
Living in a Nursing Home Setting. 
 
 
 
 
Introduction 
The nursing home was privately owned and provided care for 70 older people needing 
long term care. Residents had a range of co-morbidities including dementias for which 
the home had a dedicated unit. No residents had pressure sores and only one resident 
had an indwelling external urinary catheter. Two registered nurses administered all 
medications during 12-hour day and night shifts. Each resident with Parkinson’s 
disease was over 75 years of age and all had been prescribed levodopa for at least 4 
years. They were at an advanced stage and had co-morbidities that included chronic 
obstructive pulmonary disease and dementia. Although only numbering 7 residents 
my experience of the daily nursing challenges posed by management of their levodopa 
medication gave rise to this article.  
 
Parkinson’s Disease 
James Parkinson (1817), a London physician, first described Parkinson’s disease in ‘An 
essay on the shaking palsy’. It is caused by an imbalance between two 
neurotransmitters called dopamine and acetylcholine that communicate with 
voluntary muscle cells to produce smooth movement. Dopamine is produced in the 
largest basal ganglia structure, the corpus striatum, comprising the caudate and 
lentiform nuclei (Figure 1). The basal ganglia structures lie deep in the brain and 
control autonomic movements of skeletal muscle (Tortora and Grabowski, 2013). The 
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action of dopamine on muscle is inhibitory while that of acetylcholine is excitatory. In 
Parkinson’s disease dopamine levels are reduced resulting in a loss of inhibitory 
influences on the excitatory mechanisms of acetylcholine. This produces the 
disordered movement of increased cholinergic activity characteristic of Parkinson’s 
disease (Davie, 2008). Dopamine is not used to treat Parkinson’s because it cannot 
cross the blood-brain barrier. Its amino-acid precursor levodopa, can and is used to 
replenish depleted dopamine in the brain (JFC, 2014). Parkinson’s disease is among 
the most common chronic degenerative conditions of the nervous system in Western 
Europe.  
 
Globally, an estimated ten million people are living with Parkinson’s (Parkinson’s 
Disease Foundation, 2016). Due to difficulties diagnosing Parkinsonism under-
recognition of cases is widely acknowledged (Weerkamp et al, 2014). Recent studies in 
North East Scotland (Caslake et al, 2013), and North East England (Duncan et al, 2014) 
reported an annual incidence of 17.9 and 15.9 per 100 000 respectively. Across the UK 
the prevalence rate for Parkinson’s is reported to be 27.4 per 10,000 of the population 
(Parkinson’s UK, 2009) with no major geographical variations in England and Wales 
(Wickremaratchi et al, 2009). With increasing longevity, it is expected that prevalence 
rates will rise and Parkinson’s UK (2009) forecast a 26.7% increase over their 2009 
prevalence figures by 2020.  
 
Of note is the marked difference in prevalence between females, 24.1 per 10,000, and 
males, 30.9 per 10,000 (Parkinson’s UK, 2009).  Risk of Parkinson’s is far greater in 
people over 60 years (Mao et al, 2013), with the highest prevalence rate among 
people aged over 80 years (Horsfall et al, 2013). Onset can be early in life during the 
40’s and 50’s (Wickremaratchi et al, 2009).  Despite possible negative impact on the 
health and wellbeing of caregivers and withstanding the complex care requirements of 
Parkinson’s, most people in the UK continue to live in their own homes cared for by 
their partner who receive varied formal support. With disease progression their 
support needs increase in areas such as symptom management, lifestyle adjustment, 
relationship change and planning for the future (Lageman et al, 2015).   
 
The annual economic impact of Parkinson’s for the UK is estimated at £3.3 billion. This 
includes the direct costs of hospital admission and nursing home care associated with 
progressive disability and co-morbidity (Findley, 2007). Indeed, 55% of people with 
Parkinson’s die in hospital and 36% die in institutional care (Porter et al, 2010).   It is 
not known how many people affected by Parkinson’s live in nursing homes in the UK 
but Porter et al (2010) report 1.6%. The strongest predictors of admission to nursing 
homes include old age, hallucinations, dementia, physical dependence and a high falls 
rate (Buchanana et al, 2008). Other risk factors include living alone, impairment to 
engage in activities of daily living and depression (Makoutonina et al 2010).  This 
information is important to inform the clinical management of Parkinson’s and to 
anticipate the support needs of caregivers so that people affected can stay at home as 
long as possible.  
 
  
Diagnostic Criteria 
The starting point for optimal management of Parkinson’s disease is an accurate 
diagnosis (Weerkamp et al, 2014). Therefore people with suspected Parkinson’s 
disease should be referred quickly without treatment for specialist diagnosis (NICE, 
2015a). This is because Parkinson’s is difficult to diagnose as there are no specific 
markers to identify its onset. Cardinal diagnostic criteria are motor features. They 
include bradykinesia plus at least one clinical feature from rigidity, tremor and 
postural instability (Table 1) (Parkinson’s UK, 2015). Non-motor symptoms encompass 
multiple body systems and can impact on the quality of daily life experienced by 
residents (Table 1) (NICE, 2015b). Combined with the motor symptoms they can 
increase a resident’s need for assistance with a range of activities of daily living (NICE, 
2015c). 
 
Levodopa Treatment 
Levodopa is a dopaminergic drug used to stimulate dopamine production and 
control cholinergic excitation due to unopposed acetylcholine (Greenstein 
and Gould, 2009). To maintain good function and minimise motor 
complications the dose of levodopa should be as low as possible (NICE, 
2015c). It is generally combined with a dopa decarboxyalase inhibitor, 
carbidopa in co- careldopa (Sinemet) or banserazide in co-beneldopa 
(Madopar) (JFC, 2014). Dopa decarboxylase is an enzyme that inhibits the 
metabolism of levodopa to dopamine allowing a greater percentage of 
levodopa to cross the blood-brain barrier. This achieves effective therapeutic 
brain-dopamine concentrations. When used in combination with a dopa 
decarboxyalase inhibitor levodopa is well tolerated in older or frail people, 
residents with severe symptoms and those who have co-morbidity (Reichmann, 2016).  
However, it should be used cautiously in residents who have a history of convulsions, 
severe pulmonary or cardiovascular disease, peptic ulcer, psychiatric illness, renal or 
hepatic impairment and endocrine disorders such as diabetes mellitus and 
osteomalacia (JFC, 2014).   
 
Knowledge of medication side effects is essential. Levodopa has complex side effects 
that require careful monitoring allowing timely adjustment of medication to minimize 
impact on quality of life (Box 1)(Chan et al, 2008). Impulsive Control Disorder is 
reported in approximately 15-20% of people affected by Parkinson’s (Weintraub et al, 
2010). It is commonly expressed in behaviours such as uncontrollable shopping, 
gambling, eating, sex, and hobbies (Wiess and Marsh, 2012). Management of 
hallucinations and illusions is challenging particularly when the resident has dementia. 
Although these symptoms may result from levodopa treatment it is necessary to rule 
out causes such as delirium, pulmonary or urinary infections (Rabey, 2009). In the 
nursing home setting a nurse should discuss these issues with the resident’s GP or 
consultant as soon as possible.    
 
Side effects of levodopa also include abnormal involuntary movements (dyskinesias) 
that manifest as ‘chorea’ or ‘dystonic’ symptoms. Chorea symptoms range from 
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fidgeting movements to uncontrolled movement of the arms and legs. Dystonic 
symptoms include sustained painful muscle contractions affecting the neck, trunk and 
limbs (Vernon, 2009). Dyskinesias can occur when levodopa and dopamine reach 
maximum dose concentrations in the brain, termed peak-dose dyskinesias. When the 
dose of levodopa is very low in the brain dystonia can occur (Calabresi, 2010).  
Although there is no recognised first choice medication for Parkinson’s (NICE, 2015c) 
no other pharmacological interventions currently available demonstrate superior 
clinical benefits to levodopa (Mao et al, 2013). It remains the preferred drug to control 
motor symptoms particularly in advanced stages of Parkinson’s disease (Poewe et al, 
2010) and is the drug that physicians have most clinical experience in prescribing 
(Schapira et al, 2009). Carefully managed it can contribute to an improved quality of 
life but does not slow or prevent disease progression. For these reasons it is likely that 
levodopa medication will be one of the main drugs administered by in nursing home 
settings. 
 
Pharmacokinetic Aspects of Levodopa 
Pharmacokinetics studies the body’s influence on a drug over time during the 
processes of absorption, distribution, metabolism and excretion (Young, 2008). This 
knowledge enables nurses to understand factors that influence the maintenance of 
effective therapeutic brain-dopamine concentrations using levodopa. It has been 
known for some time that there is high variability between people in how the body 
deals with levodopa (Nutt and Fellman,1984). Parkinson’s disease can also fluctuate 
from day to day even when the same dose of levodopa is administered at the right 
time (Parkinson’s UK, 2013). Factors known to influence the pharmacokinetics of 
levodopa include sex and advanced age, low body weight, slowed gastric emptying 
and food such as fat or protein. Discerning medication management can positively or 
adversely influence some of these factors. 
 
The rate of gastric emptying is described as ‘key’ to levodopa absorption (Crevoisier et 
al, 2003). Meals provided prior to or concurrent with the administration of levodopa 
can delay its delivery to the intestinal absorption sites. This will delay and reduce its 
availability to the body, termed bioavailability. Suboptimal ingestion of levodopa due 
to slowed gastric emptying, missed doses or irregular administration of drugs can 
contribute to disabling motor fluctuations and increases in non-motor symptoms 
particularly as Parkinson’s progresses (European Parkinson’s Disease Association, 
2015). Levodopa should be administered at least 30 minutes before residents eat 
protein to prevent interference with its absorption (Parkinson’s UK, 2013). A full 
stomach also delays absorption of the drug (Crevoisier et al, 2013). Because protein 
and levodopa compete for transport across the intestinal wall and the blood-brain 
barrier possible motor fluctuations after meals can be minimised by redistribution of a 
resident’s protein intake over the course of the day (Barichella, 2006). 
 
Absorption of levodopa is erratic achieving variable bioavailability even when 
controlled-release levodopa is used (Brooks, 2008). With immediate-release levodopa 
motor improvement occurs 30 to 90 minutes after administration. Controlled-release 
  
formulations maintain levodopa levels for longer periods but their slower absorption 
increases motor improvement latency. ‘Improvement latency’ is the period of time 
after taking a drug to its pharmacological effect (Olanow et al, 2009). On this basis 
controlled-release and immediate-release formulations can be administered as a 
morning dose. These medications can help to maintain optimal control of motor 
response fluctuations (Poewe et al, 2010). This pharmacokinetic knowledge enables 
nurses working in long term settings to produce person-centered care plans that 
support safe and effective medication management. For example, by documenting a 
resident’s specific drug administration requirements in relation to their meals.  
 
Pharmacodynamic Aspects of Levodopa 
Pharmacodynamics is the study of how drugs act on the body (Greenstein and Gould, 
2009). With disease progression and long-term use the capacity of levodopa to treat 
the motor symptoms of Parkinson’s disease decreases. This is because it takes less 
time for levodopa medication in the body to be reduced by 50% referred to as the 
drug’s half-life. Because the half-life of levodopa is shortened the period of time it 
produces an effect is correspondingly reduced (Chan et al, 2005a, 2005b). When this 
happens residents experience fluctuations from ‘ON’ periods when they experience 
motor benefit to ‘OFF’ periods when they no longer benefit from the drug (Figure 
2)(Mao et al, 2013; Contin and Martinelli, 2010).   
 
Adding Catechol-O methyltransferase (COMT) inhibitors (entacapone or tolcapone) to 
levodopa can improve fluctuating motor responses by increasing ‘ON’ periods and 
decreasing ‘OFF’ periods (Stocchi and De Pandis, 2006; Leegwater-Kim and Waters, 
2007). COMT inhibitors increase the half-life of levodopa by blocking the break-down 
of levodopa into dopamine before it crosses the blood-brain barrier. This is important 
because dopamine cannot cross the blood-brain barrier. By allowing more levedopa to 
reach the brain COMT inhibitors can reduce ‘OFF’ periods (Vernon, 2009). They have 
wide ranging side effects that require careful monitoring by nurses (Box 2) (JFC, 2014). 
Tolcapone should only be prescribed under specialist supervision due to the risk of 
hepatotoxicity (JFC, 2014). Monitoring liver function is therefore important and this 
should be clearly communicated by nurses in the resident’s person-centered care plan 
(Grandas and Hernández, 2007; Mizuno et al, 2007). 
 
Monoamine oxidase type-B (MAO-B) inhibitors (selegiline and rasagaline) are licensed 
to use alone or in combination with levodopa to treat ‘OFF’ periods in Parkinson’s 
disease (JFC, 2014). They block the action of monoamine oxidase type-B, an enzyme 
that breaks down levodopa in the brain. In this way it prolongs the action of levodopa 
thereby supporting prescription of smaller levodopa doses (Greenstein and Gould, 
2009). Nurses need to monitor for their wide ranging side effects (Box 3) (JFC, 2014). 
Selegiline combined with levodopa should be avoided or used cautiously for residents 
who have postural hypotension. Its abrupt withdrawal must be avoided (JFC, 2014). 
Application of pharmacodynamic knowledge to person-centered monitoring and 
assessment enables nurses to identify specific observations they should be make in 
relation to each resident. For example, documentation of the need to monitor 
  
resident response and end-of-dose ‘OFF’ periods.  
 
Safe Management of Levodopa 
Registered nurses have a responsibility to ensure safe and reliable administration of 
medication and to monitor for side-effects (NMC, 2010; An Bord Altranais, 2007). 
Combining levodopa with decarboxyalase inhibitors has the important benefit of 
enabling use of lower levodopa doses helping to limit side-effects. The therapeutic 
success of this combination is reflected in the rare reporting of side effects as being 
dose-limiting (JFC, 2014). However, when combined with the exact titration 
requirements of levodopa medications the possibility of adverse interactions is 
increased (Williams et al, 2008).  
 
From the beginning to the end of a resident’s stay nurse documentation should reflect 
person-centered care (Jefferies et al, 2010). It is a fundamental practice approach 
expected of nurses working with older people (An Bord Altranais, 2009) and views the 
nurse/resident as a collaborative partnership in clinical decision-making. Before 
admission to the nursing home a comprehensive pre-admission assessment should be 
conducted incorporating a detailed medication history. McCormack and McCance 
(2006) suggest a biographical approach as this captures the values, beliefs and 
preferences of the person and ‘fosters a connectedness between the patient and the 
caregiver’ (Broderick and Coffey, 2013, p310). Thus, medication management should 
aim to ‘empower people with Parkinson's disease to participate in judgments and 
choices about their own care’ (NICE, 2015d, p3). 
 
Evidence shows that incomplete or incorrect documentation like omission of allergy 
status places residents at risk (National Patient Safety Agency, 2007). Pharmacological 
control through administration of levodopa medication at the ‘right time’ (Parkinson’s 
UK, 2016a; 2016b) is central to maintaining the independence and wellbeing of 
residents with Parkinson’s. Routine removal of a resident’s medication control on 
admission to a nursing home will result in anxiety that nurses might not administer 
their Parkinson’s medication on time. ‘Getting their medication on time is one of the 
most basic, important things for people with this condition’ (Parkinson’s UK, 2013, 
p41, wife caregiver). Asking previously self-medicating residents to hand over control 
of their medication can feel like an attack on their precious but declining 
independence. The importance of residents taking their Parkinson’s medication on 
time cannot be understated.  It is critical to the maintenance of the uniform 
stimulation of the brains dopamine receptors so that their parkinsonian motor 
symptoms are controlled. This helps to maximize each resident’s independence and 
quality of life. Whether administration is by nurses or residents each resident’s care 
plan should communicate medication times especially if they lie outside the usual drug 
round times. 
 
Medication administration requirements at meal times should be documented 
(Parkinson’s UK, 2013) so that residents are protected from increased motor and non-
motor symptoms due to suboptimal ingestion of levodopa (European Parkinson’s 
  
Disease Association, 2015). As stated care planning should identify any specific 
medication related observations the nurse should monitor. For levodopa the response 
and end-of-dose wearing off should be noted. Revision of medication to improve a 
resident’s motor function can produce changes in their daily energy expenditure 
resulting in weight loss or gain. Routine assessment of resident’s nutritional status can 
check their diet provides sufficient energy intake and ensure early identification of 
weight loss (Cereda et al, 2010). 
 
Medication regimes may include treatment for non-motor manifestations as well as 
for co-morbidities. Deterioration in pulmonary and cardiovascular disease, psychiatric 
illness or endocrine disorders may increase levodopa medication risk (JFC, 2014). 
There should be regular multi-disciplinary review with the prescribing doctor of 
changing needs to ensure maintenance of the resident’s quality of life and wellbeing 
(NICE, 2015d). Nurses need to be aware of the potential risk of acute akinesia or 
neuroleptic malignant syndrome if antiparkinsonian medication is abruptly withdrawn 
or fails suddenly due to poor absorption such as if a resident has gastroenteritis (NICE, 
2016c). 
 
Medication concordance 
The term ‘concordance’ embraces a consensual person-centered approach to 
medication management that places emphasis on a consultative non-judgmental 
partnership between resident and nurse. In contrast the term ‘compliance’ shouts 
judgmental professionals and reinforces the notion of passive residents (Haynes et al, 
2005). NICE (2015c) advises the choice of treatment should consider a resident’s 
presenting clinical features and their lifestyle. It also states that the resident’s 
medication preference should only be determined after the short and long-term 
benefits and drawbacks of their medication choices have been explained. Medication 
concordance is important. It can slow a resident’s disease progression, prevent 
complications, help achieve optimal wellbeing and improve quality of life (Williams et 
al, 2008). 
 
‘Sub-optimal compliance’ is significant if less than 80% of medication is taken within 
prescribed doses and intervals. Increasing complexity of medication regimen is 
strongly correlated with sub-optimal compliance (Malek and Grosset, 2015). Levodopa 
has a short plasma half-life and therefore requires multiple daily doses that can 
produce marked swings of therapeutic effect. Resulting motor fluctuations can lead to 
concordance issues due to the frustration felt by residents of their debilitating effect. 
Development of individualised simple person-centered treatment plans can improve 
concordance by residents and nurses. Complex regimes may be viewed as a burden 
(Fargel et al, 2007). 
 
Didactic sensitive discussion of the medication regimes with residents can help to 
encourage their concordance. Nurses need to spend time with residents who have 
depression and dementia to facilitate medication concordance (Daley et al, 2012). 
Respect of dignity and rights can be shown by nurses adopting a medication 
  
administration ethos that views their role as acting ‘on behalf of the resident rather 
than to the resident’ (Centre for Policy on Aging, 2011). 
 
Education and Support 
The 3rd World Parkinson Congress (World Parkinson Coalition, 2016) championed the 
empowerment of people living with Parkinson’s to be involved their care. Parkinson’s 
is challenging because it is often characterised by changes in symptoms from one 
moment to the next as in ON/OFF syndrome. This can result in loss of confidence and 
independence (Mao et al, 2013). Self-help education programmes develop self-
regulation skills through activities that include stress management, dealing with 
depression or anxiety and maintaining social competence (Macht et al, 2007; A’Campo 
et al, 2010).  
 
Healthcare professionals that lack neurological expertise are likely to contribute to 
poor clinical outcomes for people who have Parkinson’s (Royal College of Physicians, 
2011). Universal access of nursing home staff, residents and their families to the 
expertise of Parkinson’s Disease Nurse Specialists would help to address this issue. 
NICE (2015d) recommend this arrangement for purposes of advice, clinical monitoring 
and medication adjustment. Nurse Specialists have been shown to relieve the negative 
impact of Parkinson’s on the daily lives of individuals and families affected (Hellqvist 
and Berterö, 2015; RCN, 2010), ‘… She changed my life from being a scared, shaking 
mess to a much happier person. She gives me hope’ (Parkinson’s UK, 2013, p14).  
 
A survey of people with Parkinson’s admitted to hospital, and who were not self- 
medicating, found nearly 33% did not get their medication on time every time and that 
25% felt this prolonged their hospital stay (Parkinson's Disease Society, 2008). It is so 
important for nurses working in long term care to engage in training on medication 
management specific to Parkinson’s. Free resources and on-line courses are available 
for nursing home staff (Parkinson’s UK, 2016c; 2016d) including a ‘Get It On Time’ 
training DVD (Parkinson’s UK, 2016a; 2016b). This testimony captures the positive 
impact training of nurses can have for people with Parkinson’s, ‘Thanks to the Get It 
On Time campaign, staff at my local hospital now understand that I need my 
medication on time …’ (Parkinson’s UK, 2011, p12).  
 
Conclusion 
This case study has explored the pharmacokinetic and pharmacodynamic aspects of 
levodopa medication because this knowledge underpins safe and effective person-
centered medication management in nursing home settings. Discussions on safe 
medication management and concordance reveal the substantial daily challenges faced 
by nurses caring for residents who have Parkinson’s disease. In particular it explains why 
administration of Parkinson’s medication at the ‘right time’ is crucial to the health and 
wellbeing of these residents. Future practice should continue to develop a person-centered 
approach to medication management that is embedded in excellent care planning. 
Wherever possible it should support residents to self-medicate. Management of 
medication treatment for long term conditions is a key nursing role in nursing home 
  
settings. Ongoing professional development and updating in pharmacology and 
medication management relevant to the conditions of residents can equip nurses to 
maintain the independence of residents and enhance their quality of life. 
 
 
References 
Aarsland D, Larsen J, Tandberg E et al (2000) Predictors of nursing home placement in 
Parkinson’s disease: a population-based, prospective study. Journal of American 
Geriatric Society. 48, 8, 938–42.  
 
A’Campo L, Wekking E, Spliethoff-Kamminga N et al (2010) The benefits of a 
standardized patient education program for patients with Parkinson’s disease and 
their caregivers. Parkinsonism and Related Disorders. 16, 2, 89–95.  
 
An Bord Altranais (2009) Professional Guidance for Nurses Working with Older People. 
Dublin: An Bord Altranais. 
 
An Bord Altranais (2007) Guidance to nurses and Midwives on Medication 
Management. Dublin: An Bord Altranais. 
 
Barichella M, Marczewska A, De Notaris R et al (2006) Special low-protein foods 
ameliorate postprandial off in patients with advanced Parkinson’s disease. Movement 
Disorders. 21, 10, 682–687. 
 
Broderick M, Coffey A (2013) Person-centered care in nursing documentation. 
International Journal of Older People Nursing. 8, 4, 309–318. 
 
Brooks D (2008) Optimising levodopa therapy for Parkinson’s disease with 
levodopa/carbidopa/entacapone: implications for a clinical and patient perspective. 
Neuropsychiatric Disease Treatment. 4, 1, 39-47.   
 
Buchanan R, Wang S, Huang C et al (2008) Analyses of nursing home residents with 
Parkinson's disease using the minimum data set. Parkinsonism & Related Disorders. 8, 
5, 369-380.  
 
Calabresi P, Di Filippo M, Ghiglieri V, (2010) Levodopa-induced dyskinesias in patients 
with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurology, 9, 11, 
1106–1017. 
 
Caslake R, Taylor K, Scott N et al (2013) Age, gender and socioeconomic status-specific 
incidence of Parkinson’s disease and parkinsonism in North East Scotland: The PINE 
study. Parkinsonism and Related Disorders. 19, 5, 515-521.  
 
Centre for Policy on Aging (2011) Revised April 2012. Managing and administering 
medication in care homes for older people. Tavis House, London: Centre for Aging.  
http://www.cpa.org.uk/information/reviews/Managing_and_Administering_Medic 
ation_in_Care_Homes.pdf. 
  
Cereda E, Pezzoli G, Barichella M (2010) Role of an electronic armband in motor 
function monitoring in patients with Parkinson’s disease. Nutrition. 26, 2, 240-242. 
 
Chan D, Cordato D, O'Rourke F (2008) Management for motor and non-motor 
complications in late Parkinson's disease. Geriatric. 63, 5, 22–27.   
 
Chan P, Nutt J, Holford N (2005a) Importance of Within Subject Variation in Levodopa 
Pharmacokinetics: A 4 Year Cohort Study in Parkinson’s Disease. Journal of 
Pharmacokinetics and Pharmacodynamics. 32, 3-4, 307-331. 
 
Chan P, Nutt J, Holford N (2005b) Pharmacokinetic and Pharmacodynamic Changes 
During the First Four Years of Levodopa Treatment in Parkinson’s Disease. Journal of 
Pharmacokinetics and Pharmacodynamics. 32, 3-4, 459-484. 
 
Contin M, Martinelli P (2010) Pharmacokinetics of levodopa. Journal of Neurology.  
257, 2, S253–61. 
 
Crevoisera C, Zerr P, Calvi-Gries F et al (2003) Effects of food on the pharmacokinetics 
of levodopa in a dual-release formulation. European Journal of Pharmaceutics and 
Biopharmaceutics.  55, 1, 71–76. 
 
Daley D, Myint P, Gray R, et al (2012) Systematic review on factors associated with 
medication non-adherence in Parkinson’s disease. Parkinsonism Related Disorders. 18, 
10, 1053- 1061. 
  
Davie C (2008) A Review of Parkinson’s Disease. British Medical Bulletin. 86, 107-129. 
 
Duncan G, Khoo T, Coleman S et al (2014) The incidence of Parkinson’s disease in the 
North-East of England. Age and Ageing. 43, 2, 257–263.  
 
European Parkinson’s Disease Association (2015) Treatments and Therapies  (Available 
from URL on 06.08.2016) http://www.epda.eu.com/en/pd-info/treatment-and-
therapies/ 
 
Fargel M, Grobe B, Oesterle E, Hastedt C, et al (2007) Treatment of Parkinson’s 
disease: a survey of patients and neurologists. Clinical Drug Investigation. 27, 3, 207-
218. 
 
Findley L (2007) The economic impact of Parkinson’s disease. Parkinsonism and 
Related Disorders. 13, S8–S12.  
 
Grandas F, Hernández B (2007) Long-term effectiveness and quality of life 
improvement in entacapone-treated Parkinson’s disease patients: the effects of an 
early therapeutic intervention. European Journal of Neurology. 14, 3,   282–289. 
 
Greenstein B, Gould D (2009) Trounce’s Clinical Pharmacology for Nurses. 18th edition. 
Edinburgh London: Churchill Livingstone Elsevier. 
  
Haynes R, McDonald H, Garg A et al (2002) Interventions for helping patients to follow 
prescriptions for medications. Cochrane Database of Systematic Reviews. Issue 2, 1-50. 
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Figure 1 Frontal Section of the Basal Ganglia Nuclei. 
 
 
 
 
 
(Lecturio, 2016) 
 
 
 
 
 
 
 
 
 
  
 
 
  Table 1  Clinical Features of People with Parkinson’s Disease 
 
Motor Symptoms Non-Motor Symptoms 
Tremor (involuntary shaking and trembling) Bradykinesia 
(slowness in movement) Rigidity 
Postural instability (loss of postural reflexes) 
Cognitive impairment 
Bradyphrenia (slowness of thought) 
Tip-of-the-tongue phenomenon (word finding) 
Hypomimia (loss of facial expression, mask-like face) 
Dysarthria Dysphagia 
Sialorrhoea (drooling) 
Depression Apathy, fatigue 
Anhedonia (symptom of major depressive disorders. Loss of 
interest in previously rewarding enjoyable activities) 
Other behavioural /psychiatric issues 
Decreased arm swing Shuffling gait 
Festination (gait of quickening and shortening steps) 
Difficulty arising from chair or turning in bed 
Sensory symptoms 
Anosmia (loss of sense of smell) 
Ageusia (loss of taste functions of the tongue) Pain (shoulder, 
back) 
Paresthesias 
 
Micrographia (small cramped hand writing) Cutting food 
Feeding Hygiene 
Slow activities of daily living 
Dysautonomia (umbrella term for several medical conditions 
that cause malfunction of the autonomic nervous system) 
(orthostatic hypotension, constipation, urinary and sexual 
dysfunction, abnormal sweating, seborrhoea) Weight loss 
Glabellar reflex (primitive reflex where the eyes shut if 
the individual is tapped between the eyebrows) 
Blepharospasm (sustained enforced closing of the eye 
lids. Can be painful. May be called eye dystonia) 
Dystonia (abnormal muscle tone resulting in muscle 
spasm and abnormal posture) 
Striatal deformity (deformities of the hand and the foot) 
Scoliosis (a sideways curvature of the spine) 
Camptocormia (abnormal severe involuntary forward 
flexion of the thoracolumbar spine) 
Sleep disorders 
(Rapid Eye Movement behaviour disorder, vivid dreams, 
daytime drowsiness, sleep fragmentation, restless legs 
syndrome) 
(Adapted from Jankovic, 2008) 
 
 
 
 
 
 
 
 
 
  
 
 
Box 1 Side effects of Levodopa 
 Nausea, vomiting 
 Taste disturbances, anorexia 
 Dry mouth 
 Postural-hypotension 
 Hallucinations, illusions 
 Drowsiness 
 Mood change, depression 
 Alteration of libido 
 Impulsive Control Disorder 
(Chan et al, 2008)  
 
 
 
 
 
 
 
Box 2 Side effects of COMT inhibitors 
 Nausea, vomiting 
 Dry mouth 
 Abdominal pain, constipation, diarrhoea 
 Reddish brown discolouration of the urine 
 Sweating 
 Confusion, hallucinations 
 Dizziness 
 Fatigue, insomnia 
 Dyskinesias 
 Hepatotoxicity (Tolcapane)  
(JFC, 2014) 
 
 
 
 
 
 
  
 
 
 
Box 3 Side effects of MAO-B inhibitors 
 Nausea 
 Dry mouth, stomatitis, mouth ulcers 
 Nasal congestion 
 Constipation, diarrhoea 
 Sweating 
 Hair loss 
 Bradicardia 
 Hypertension, hypotension, 
 Depression 
 Headache hair loss and sweating  
 Confusion 
 Dizziness, impaired balance 
 Fatigue 
 Movement disorders, myalgia 
 (JFC, 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2 End of dose ‘wearing-off’ in levodopa treated residents 
 
 
 
(European Parkinson’s Disease Association, 2015) 
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